Scientific Advisory Board

 

Dr. Kian Tai, CHONG MD (MBBS), MRCS (Edin), MSc

Dr Chong is currently the Consultant, Adjunct Assistant Professor, co-Director of Urologic Oncology and Director of Research in the Department of Urology, Tan Tock Seng Hospital. He also manages the prospective Urology Cancer clinical databases and Tissue Repository in the Hospital. He is a board-certified Urologist and surgeon who manages complex Urologic Oncology issues, and operates using open, laparoscopic and da-Vinci robotic operating system.

As a founding member of the Singapore Urological Cancer Consortium, Dr Chong leads several research teams and is involved in Prostate, Kidney, Bladder and Testicular Cancer research. These projects include precision medicine, biomolecular, nanoparticle, bioimaging and novel biomedical device studies.

In supporting holistic care for urological cancer patients, he is also the Chairman for the Urology Cancer Multi-disciplinary Tumour Board, Urology Cancer Support Programme, Advanced Care Planning team and TTSH Prostate Cancer Support Group for patients and their family.

Dr Chong graduated from National University of Singapore with a MBBS and Master of Science. He is a member and has a postgraduate professional diploma from Royal College of Surgeons of Edinburgh. He completed his full-time Clinical Urologic-Oncology Fellowship at the prestigious Memorial-Sloan Kettering Cancer Center (MSKCC) in New York, USA. His key professional interests are the prevention, diagnosis, treatment and management of prostate cancer, kidney cancer, bladder cancer, testis cancer and penile cancer.

Dr. Zhisong, CAO PhD.

Dr Cao is currently the CEO and President of CAO Pharmaceuticals Inc. He was the Associate Laboratory Director of CHRISTUS Stehlin Foundation for Cancer Research in Houston and held various research and management positions for more than 20 years in the Organization. He has extensive experience in various field of cancer research and specializes in drug discovery. He currently, focuses on clinical development of CZ-48 oncology drug, which he invented, in US.

Dr Cao graduated with Bachelor of Science in Chemistry from Huazhong Normal University and obtained his Ph.D. in Organic Chemistry from University of Delaware. He completed his postdoctoral fellow from University of Texas Medical Branch at Galveston, Texas, and was Associate Professor of Huazhong Normal University. Dr Cao has filed 16 patents and authored more than 30 publications.